Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss

BACKGROUNDGlucagon-like peptide-1 receptor agonists (GLP-1 RAs), including dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists, have revolutionized obesity management, resulting in significant medication-driven weight loss (MDWL). Despite widespread reporting, the dermatological consequences of MDWL, including skin laxity and hair loss, remain poorly characterized in real-world populations.

AIMSTo quantify the prevalence, onset, and phenotypic characteristics of skin and hair changes during MDWL with GLP-1 and dual GLP-1/GIP receptor agonists, and to evaluate patient-reported treatment satisfaction and health-related quality of life.

METHODSA single-center, cross-sectional survey was administered between June 20 and July 15, 2025. A total of 504 adults who were using GLP-1 RA or dual GLP-1/GIP RA medications completed a 55-item HIPAA-compliant electronic questionnaire capturing demographics, medication history, weight loss, cutaneous and/or trichological changes, treatment satisfaction, and psychological well-being.

RESULTSThe cohort was predominantly female (89.9%), with a mean age of 52.8 ± 11.2 years and a mean pre-treatment BMI of 37.5 ± 8.1. Skin changes were reported by 38.7% of respondents, characterized primarily by facial volume loss (10.9%), sagging (8.3%), and jowling (7.7%). Onset occurred within the first 5 months of therapy for 55.1% of these participants. Skin changes correlated with age > 55 years and weight loss of > 20 lb/9.1 kg, with consistent prevalence across drug formulations. Hair changes were reported by 38.9% of the cohort, dominated by shedding (20.8%) and thinning (19.0%). Of those reporting shedding, 42.0% experienced onset despite being on treatment for only 1–3 months. Distinct racial phenotypes emerged in hair changes: White users frequently reported classic telogen effluvium-type changes (shedding: 23.8%; thinning: 22.6%), whereas Black/African American users reported disproportionately higher rates of structural hair changes (dryness: 15.3%; breakage: 12.1%). Overall treatment satisfaction was exceptionally high at 92.0%, accompanied by significant improvements in body image (84.0%) and self-confidence (68.5%).

CONCLUSIONSDermatological cutaneous and trichological changes are frequent, early-onset consequences of MDWL that correlate with weight loss speed and magnitude, exhibiting distinct phenotypes across age and race/ethnicity. These findings highlight the need for personalized proactive integrative dermatological care models that should be initiated early and maintained through the weight loss medication journey.

Abstract from Crossref